Markus Rehberg

Markus Rehberg is an Applied Professor in Physiology at Ludwig-Maximilians-Universität München and a Principal Investigator at the Institute of Lung Health and Immunity (LHI) / Comprehensive Pneumology Center (CPC), Helmholtz Munich. His research focuses on understanding the transition from health to chronic lung disease through innate immune processes at the alveolar barrier, particularly in response to environmental challenges like particles and viruses.

• Education: Dr. rer. nat. in Molecular and Cell Biology from Ludwig-Maximilians-Universität München.
• Postdoctoral training: Advanced in vivo two-photon microscopy, nano-bio interactions, and innate immunity.

Research interests center on innate immunity, nanotoxicology, quantum dots, inhalation toxicity, and real-time in vivo imaging. His work utilizes intravital microscopy and ventilator-assisted nanoparticle aerosol inhalation to study cellular dynamics in murine lung models.

Recent publications highlight trends in AI-powered 3D imaging, quantum dot effects on pulmonary inflammation, and microplastic fiber toxicity in airways. Techniques include advanced imaging and nanoagent development for therapeutic and diagnostic applications.

Rehberg is involved in EU-funded projects

• BOW, developing biomimetic nanocarriers for inhalation therapy.
• nanoPASS, studying nanomaterial lung toxicity.

His laboratory specializes in Lung Intravital Microscopy and collaborations across nanoscience, pulmonary medicine, and immunology.